Ansofaxine (original) (raw)
Toludesvenlafaxine (former developmental code names LY03005, LPM570065), also known as ansofaxine or as 4-methylbenzoate desvenlafaxine, is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) which is under development by Luye Pharma Group for the treatment of major depressive disorder (MDD). It is described as an SNDRI and prodrug to desvenlafaxine. However, unlike desvenlafaxine, which has in vitro IC50 values of 53 nM and 538 nM for inhibition of serotonin and norepinephrine reuptake, respectively, toludesvenlafaxine has respective in vitro IC50 values of 723 nM, 763 nM, and 491 nM for serotonin, norepinephrine, and dopamine reuptake inhibition. As of July 2018, the drug is in preregistration for MDD in the United States, the European Union, Japan, and China. In December 2018
| Property | Value |
|---|---|
| dbo:abstract | Toludesvenlafaxine (former developmental code names LY03005, LPM570065), also known as ansofaxine or as 4-methylbenzoate desvenlafaxine, is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) which is under development by Luye Pharma Group for the treatment of major depressive disorder (MDD). It is described as an SNDRI and prodrug to desvenlafaxine. However, unlike desvenlafaxine, which has in vitro IC50 values of 53 nM and 538 nM for inhibition of serotonin and norepinephrine reuptake, respectively, toludesvenlafaxine has respective in vitro IC50 values of 723 nM, 763 nM, and 491 nM for serotonin, norepinephrine, and dopamine reuptake inhibition. As of July 2018, the drug is in preregistration for MDD in the United States, the European Union, Japan, and China. In December 2018 the drug is in phase III trial in the United States and China. In March of 2020 the FDA accepted Luye Pharma's new drug application for ansofaxine. In December 2021 Luye Pharma released results from phase II clinical trials on ansofaxine. Luye Pharma Group has issued the brand name Ruoxinlin for the upcoming medication Ansofaxine. In November of 2022 Ruoxinlin was approved for MDD in China. (en) |
| dbo:casNumber | (hydrochloride) 916918-84-8 |
| dbo:fdaUniiCode | V6Z6K3OQX4 |
| dbo:pubchem | 56955395 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Ansofaxine.svg?width=300 |
| dbo:wikiPageExternalLink | https://adisinsight.springer.com/drugs/800039935 |
| dbo:wikiPageID | 48814280 (xsd:integer) |
| dbo:wikiPageLength | 5724 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1123080618 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Desvenlafaxine dbr:United_States dbr:In_vitro dbr:List_of_investigational_antidepressants dbc:Cyclohexanols dbc:Experimental_drugs dbc:Phenethylamines dbc:Phenols dbc:Tertiary_alcohols dbr:Oral_administration dbr:Major_depressive_disorder dbr:Prodrug dbc:Antidepressants dbr:European_Union dbr:Norepinephrine dbc:Serotonin–norepinephrine–dopamine_reuptake_inhibitors dbr:Japan dbr:Hydrochloride dbr:China dbr:Dopamine dbr:Serotonin dbr:Serotonin–norepinephrine–dopamine_reuptake_inhibitor dbr:Reuptake |
| dbp:c | 24 (xsd:integer) |
| dbp:casNumber | 916918 (xsd:integer) |
| dbp:casSupplemental | (en) |
| dbp:chemspiderid | 13114670 (xsd:integer) |
| dbp:h | 31 (xsd:integer) |
| dbp:iupacName | 4 (xsd:integer) |
| dbp:n | 1 (xsd:integer) |
| dbp:o | 3 (xsd:integer) |
| dbp:pubchem | 56955395 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_administration |
| dbp:smiles | Cc1cccCOc2cccCC3O (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | QKYBZJLEMOZFFU-UHFFFAOYSA-N (en) |
| dbp:synonyms | LY03005; LPM570065; 4-Methylbenzoate desvenlafaxine hydrochloride (en) |
| dbp:unii | V6Z6K3OQX4 (en) |
| dbp:width | 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Nervous-system-drug-stub dbt:Phenethylamines dbt:Reflist dbt:Short_description dbt:Abbrlink dbt:Fdacite dbt:Antidepressants dbt:Monoamine_reuptake_inhibitors |
| dcterms:subject | dbc:Cyclohexanols dbc:Experimental_drugs dbc:Phenethylamines dbc:Phenols dbc:Tertiary_alcohols dbc:Antidepressants dbc:Serotonin–norepinephrine–dopamine_reuptake_inhibitors |
| gold:hypernym | dbr:Inhibitor |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Toludesvenlafaxine (former developmental code names LY03005, LPM570065), also known as ansofaxine or as 4-methylbenzoate desvenlafaxine, is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) which is under development by Luye Pharma Group for the treatment of major depressive disorder (MDD). It is described as an SNDRI and prodrug to desvenlafaxine. However, unlike desvenlafaxine, which has in vitro IC50 values of 53 nM and 538 nM for inhibition of serotonin and norepinephrine reuptake, respectively, toludesvenlafaxine has respective in vitro IC50 values of 723 nM, 763 nM, and 491 nM for serotonin, norepinephrine, and dopamine reuptake inhibition. As of July 2018, the drug is in preregistration for MDD in the United States, the European Union, Japan, and China. In December 2018 (en) |
| rdfs:label | Ansofaxine (en) |
| owl:sameAs | yago-res:Ansofaxine wikidata:Ansofaxine https://global.dbpedia.org/id/2N8XJ |
| prov:wasDerivedFrom | wikipedia-en:Ansofaxine?oldid=1123080618&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Ansofaxine.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Ansofaxine |
| is dbo:wikiPageRedirects of | dbr:LPM-570,065 dbr:LPM-570065 dbr:LPM570065 dbr:LPM_570065 dbr:LY-03005 dbr:LY03005 dbr:LY_03005 dbr:Toludesvenlafaxine dbr:Ansofaxine_hydrochloride |
| is dbo:wikiPageWikiLink of | dbr:Desvenlafaxine dbr:C24H31NO3 dbr:Liafensine dbr:Serotonin–norepinephrine–dopamine_reuptake_inhibitor dbr:LPM-570,065 dbr:LPM-570065 dbr:LPM570065 dbr:LPM_570065 dbr:LY-03005 dbr:LY03005 dbr:LY_03005 dbr:Toludesvenlafaxine dbr:Ansofaxine_hydrochloride |
| is foaf:primaryTopic of | wikipedia-en:Ansofaxine |
